Dr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.

S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC

Sign up to save your podcasts

S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC

S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC

More shows like OncLive® On Air

JAMA Clinical Reviews

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

ASCO Daily News

The Daily

OncoPharm

The Readout Loud

The Uromigos

Oncology Today with Dr Neil Love

BioCentury This Week

Decera Clinical Education Oncology Podcast

Biotech Hangout

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions